Online inquiry

IVTScrip™ mRNA-Anti-KDR, 1121B(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ85MR)

This product GTTS-WQ85MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets KDR gene. The antibody can be applied in Breast Cancer, Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_002253.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3791
UniProt ID P35968
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-KDR, 1121B(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ85MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3319MR IVTScrip™ mRNA-Anti-lukG&lukH, ASN-100(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ASN-100
GTTS-WQ6107MR IVTScrip™ mRNA-Anti-IL6, COR-001(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA COR-001
GTTS-WQ1376MR IVTScrip™ mRNA-Anti-IL12B, ABT-874(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ABT-874
GTTS-WQ5900MR IVTScrip™ mRNA-Anti-IL31RA, CIM 331(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CIM 331
GTTS-WQ14785MR IVTScrip™ mRNA-Anti-CD40, SGN-40(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA SGN-40
GTTS-WQ8747MR IVTScrip™ mRNA-Anti-TNFRSF4, IBI-101(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IBI-101
GTTS-WQ7557MR IVTScrip™ mRNA-Anti-GPC3, GC33(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GC33
GTTS-WQ8994MR IVTScrip™ mRNA-Anti-IL13, IMA-638(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA IMA-638
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW